Combination treatment for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial is testing a combination of two targeted therapies for a specific type of triple-negative breast cancer. The goal is to see if adding a second drug improves the effectiveness of the first treatment in slowing the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- You must have triple-negative breast cancer that is a specific subtype called BLIS (confirmed by a special test).
- Your cancer must have come back or spread to other parts of the body, and you can have had up to 2 prior treatments for advanced disease.
- You need to be generally active, able to care for yourself, and expected to live at least 3 more months.
- Your organs (blood, liver, kidneys) need to be working well enough, with no untreated brain metastases.
- You must not have had certain prior treatments, including drugs that block blood vessel growth or certain types of targeted chemo (antibody-drug conjugates).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
This trial tests a combination of two targeted medicines given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can improve outcomes for patients with this type of breast cancer.
This study tests two treatments for advanced breast cancer that has stopped responding to a common class of drugs. It combines a targeted pill (famitinib) with an experimental antibody-drug treatment (SHR-A1811) to see if the combination works better than the antibody-drug alone.
This trial tests a new combination of a vitamin A derivative (all-trans retinoic acid), an immunotherapy drug (toripalimab), and chemotherapy for people with advanced triple negative breast cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink or control the cancer better than current treatments.
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.